Nicholas D. James, PhD, MBBS, on Clinical Implications of STAMPEDE Trial Results: Abiraterone Acetate Plus Prednisolone in Prostate Cancer
Posted: Wednesday, September 23, 2020
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research, London, discusses how the long-term STAMPEDE findings on abiraterone acetate plus prednisolone, which showed benefits in terms of survival and toxicity, fit into evolving clinical practice.
